Hansen Su, MD
Psychiatry · Chapel Hill, NCNPI 1952372591
Payments from drug & device makers
Across 324 payments — averaging $18.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$1K
- Otsuka America Pharmaceutical, Inc.$931
- Alkermes, Inc.$687
- Teva Pharmaceuticals USA, Inc.$675
- Johnson & Johnson$355
- Neurocrine Biosciences, Inc.$300
- plus $2K from 22 others
What the payments were for
- Food & beverage$5,67896%
- Education$2564%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 67 | $1,229 |
| Otsuka America Pharmaceutical, Inc. | 39 | $931 |
| Alkermes, Inc. | 30 | $687 |
| Teva Pharmaceuticals USA, Inc. | 36 | $675 |
| Johnson & Johnson | 23 | $355 |
| Neurocrine Biosciences, Inc. | 15 | $300 |
| AbbVie(2 entities) | 23 | $297 |
| Indivior Inc. | 21 | $280 |
| Lundbeck LLC | 13 | $244 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $158 |
| Shire North American Group Inc | 6 | $101 |
| Vanda Pharmaceuticals Inc. | 6 | $97 |
| Tris Pharma Inc | 5 | $84 |
| Avanir Pharmaceuticals, Inc. | 4 | $72 |
| Ironshore Pharmaceuticals Inc. | 3 | $58 |
| Rhodes Pharmaceuticals L.p. | 4 | $55 |
| Jazz Pharmaceuticals Inc. | 3 | $48 |
| Arbor Pharmaceuticals, Inc. | 3 | $47 |
| E.r. Squibb & Sons, L.L.C. | 2 | $44 |
| Corium, LLC | 2 | $27 |
| Neos Therapeutics, LP | 2 | $26 |
| Adlon Therapeutics L.p. | 2 | $26 |
| Supernus Pharmaceuticals, Inc. | 1 | $23 |
| Bausch Health US, LLC | 1 | $17 |
| Merck | 1 | $15 |
| Almatica Pharma LLC | 1 | $14 |
| Genentech USA, Inc. | 1 | $13 |
| Validus Pharmaceuticals LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$464
- ABILIFY MAINTENA$236
- LATUDA$119
- ARISTADA INITIO$116
How this compares
$5,934 in reported general payments places this provider in the 85th percentile of 1,108 psychiatry providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 48 | $559,316 |
| IngrezzaValbenazine Tosylate | 19 | $147,024 |
| CaplytaLumateperone Tosylate | 78 | $130,963 |
| VraylarCariprazine Hcl | 65 | $107,744 |
| Austedo XrDeutetrabenazine | 17 | $105,014 |
| Invega SustennaPaliperidone Palmitate | 25 | $84,252 |
| FanaptIloperidone | 35 | $76,916 |
| Abilify MaintenaAripiprazole | 26 | $76,447 |
| RexultiBrexpiprazole | 49 | $69,843 |
| AristadaAripiprazole Lauroxil | 15 | $47,159 |
| TrintellixVortioxetine Hydrobromide | 73 | $43,570 |
| BelsomraSuvorexant | 71 | $32,579 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 632 | $23,245 |
| Lurasidone Hcl | 250 | $20,562 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 25 | $19,974 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $675 | $664,33165 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $300 | $147,02419 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $931 | $146,29075 claims |
| AbbVieVraylar, Fetzima | $297 | $127,31488 claims |
| Johnson & JohnsonInvega Sustenna | $355 | $84,25225 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $97 | $76,91635 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $158 | $57,401108 claims |
| Alkermes, Inc.Aristada | $687 | $47,15915 claims |
| MerckBelsomra | $15 | $32,57971 claims |
| Indivior Inc.Suboxone | $280 | $19,97425 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,108 psychiatry providers in North Carolina.
Other psychiatry in Chapel Hill
- Samantha Meltzer-BrodyChapel Hill$909K
- Lars JarskogChapel Hill$442K
- Sandeep VaishnaviChapel Hill$415K
- David RubinowChapel Hill$340K
- Linmarie SikichChapel Hill$244K
- Diana PerkinsChapel Hill$176K
- Elizabeth RichardsonChapel Hill$45K
- Craig ChepkeHuntersville$4.1M
- James BarkerHickory$4.1M
- Mark ReynoldsDurham$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.